C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database
Aristotle Bamias,Kimon Tzannis,M. Liontos,Lauren C. Harshman,Simon J. Crabb,Y.-N. Wong,Sumanta K. Pal,Thomas Powles,Joaquim Bellmunt,U. De Giorgi,Sylvain Ladoire,Neeraj Agarwal,Evan Y. Yu,Guenter Niegisch,Cora N. Sternberg,Ajjai Alva,Sandhya Srinivas,Jonathan E. Rosenberg,Risc Investigators +18 more
Journal ArticleDOI
POS-03.126: SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men
J.P. Droz,Lodovico Balducci,Michel Bolla,Mark Emberton,John M. Fitzpatrick,Steven Joniau,M. W. Kattan,Silvio Monfardini,Judd W. Moul,Arash Naeim,H. Van Poppel,Fred Saad,Cora N. Sternberg +12 more
Journal ArticleDOI
Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
Ronald de Wit,Thomas Powles,Daniel Castellano,Andrea Necchi,Jae-Lyun Lee,Michiel S. van der Heijden,Nobuaki Matsubara,Aristotelis Bamias,Aude Flechon,Cora N. Sternberg,Alexandra Drakaki,Evan Y. Yu,S. Zimmermann,Amanda J. Long,Richard A. Walgren,Li-Ping Gao,Katherine M. Bell-McGuinn,Daniel P. Petrylak +17 more
TL;DR: Ramucirumab plus docetaxel significantly improved progression‐free survival but not overall survival in platinum‐refractory advanced UC in the RANGE trial (RANGE trial; NCT02426125).
Journal Article
S. Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the EORTC
Cora N. Sternberg,P.H.M. de Mulder,Sophie D. Fosså,S. B. Kaye,Timothy T. Roberts,A. Pawinsky,S. Daamen +6 more
Journal ArticleDOI
Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC)
Roberto Iacovelli,Matteo Santoni,G. Di Lorenzo,L. Cerbone,Massimo Aglietta,Cristina Masini,Maria Olga Giganti,Caterina Messina,Cora N. Sternberg,G. Procopio +9 more
TL;DR: The sequence sunitinib-sorafenib-everolimus- everolimus was associated with a better TTSF and OS as compared to the sequence sun itinib -sorAFenib -Everolimus, and maintained its independent prognostic role when stratified by ECOG-PS or baseline MSKCC.